查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886904

腫瘤正子斷層掃描（PET）市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察，以及2024-2032年預測

Oncology Positron Emission Tomography Scan Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 165 Pages | 商品交期: 請詢問到貨日

價格

腫瘤PET市場成長驅動因子

由於癌症發生率上升和對精準診斷影像的需求不斷增長，全球腫瘤PET市場持續擴張。 2024年市場規模為117.4億美元，預計2025年將達到123.1億美元。預計2032年將進一步成長至180.4億美元，預測期內複合年增長率（CAGR）為5.6%。 2024年，北美地區佔52.55%的市場佔有率，這主要得益於技術應用的普及、廣泛的影像基礎設施以及較高的癌症篩檢率。

PET掃描在腫瘤學中發揮重要作用，包括癌症分期、治療計劃制定和療效評估。這種使用放射性追蹤劑的非侵入性影像技術能夠檢測細胞層面的代謝活動，因此對癌症早期檢測至關重要。全球癌症發生率的不斷上升、PET基礎設施的投資以及先進PET/CT系統的出現，正在加速PET在全球的應用。

市場動態

市場驅動因素

市場擴張的主要驅動因素是全球癌症負擔的日益加重，這推動了國家篩檢計畫的實施和先進影像系統的快速普及。由於PET掃描具有較高的診斷準確性和在個人化癌症治療中的價值，世界各地的醫療機構都在採用這項技術。更新的臨床指南，例如核子醫學與分子影像學會（SNMMI）和美國國家綜合癌症網絡（NCCN）在2022年推薦使用新型PET顯影劑PYLARIFY治療前列腺癌，也推動了PET掃描的普及。

對早期診斷、精準腫瘤學和治療監測的日益重視持續推動著對PET影像的需求。根據美國癌症協會預測，到2025年，美國將新增超過313,780例前列腺癌病例，凸顯了對更先進診斷技術的迫切需求。

市場限制因子

PET系統的高昂成本仍然是一個主要挑戰，限制了其在發展中國家的普及。入門級掃描儀的價格約為475,000美元，而高端型號的價格超過750,000美元，這使得小型醫院的安裝和維護成為一項沉重的經濟負擔。此外，放射性示蹤劑的製備、人員專業技能和基礎建設也推高了營運成本。

有限的保險報銷進一步阻礙了PET的普及。在許多發展中國家，PET掃描的資金不足或僅部分報銷，這成為診斷普及的障礙。即使在已開發地區，保險也可能不涵蓋多次掃描或某些類型的癌症，從而限制了市場供應。

市場機會

將人工智慧 (AI) 整合到腫瘤學的 PET 成像中蘊藏著巨大的機會。 AI 工具可增強病灶偵測、自動進行腫瘤定量分析並提高工作流程效率。例如，西門子醫療於 2023 年推出了 Biograph Vision PET/CT，其採用先進的飛行時間成像 (TOF) 技術，可顯著提高診斷清晰度。隨著 AI 系統獲得監管部門的批准，預計其應用將加速全球 PET 成像效率的提升。

市場挑戰

放射性示蹤劑供應鏈持續存在的瓶頸構成了一項重大挑戰。 FDG 等放射性示蹤劑的半衰期很短，因此需要高效率的物流。任何延誤都會促使檢測計劃被打亂，等待時間延長。在英國，2024 年的數據顯示，92% 的癌症患者至少需要等待 31 天才能接受篩檢，部分原因是放射性追蹤劑供應瓶頸。此外，全球對有限的同位素供應商的依賴使得醫療保健系統在生產中斷時非常脆弱。

市場趨勢

一個值得注意的趨勢是向 "診療一體化" 的轉變，它將診斷性 PET 影像與標靶放射性核素治療相結合。基於 PSMA 的 PET 影像用於前列腺癌，以及用於神經內分泌腫瘤的新型示蹤劑，都顯示人們對精準腫瘤學的興趣日益濃厚。影像生物標記的進步也正在改變治療計劃，使其能夠預測和即時監測治療結果。

細分市場概覽

按付款方式

2024 年，私人保險/自費市場佔主導地位，這主要得益於患者對更快、更高品質的腫瘤診斷的需求。癌症治療費用不斷上漲也推動了私人支出的增加。由於全球致力於將PET影像技術納入政府資助的癌症項目，公共醫療市場也實現了成長。

依服務提供者劃分

2024年，醫院憑藉先進的成像基礎設施和訓練有素的放射科團隊，佔了市場主導地位。然而，由於成本效益高、等待時間短以及PET/CT投資不斷增加，預計診斷中心將成長最快。

依地區劃分

北美（2024年為61.7億美元）

該地區憑藉其強大的醫療基礎設施和先進的PET系統高普及率，在全球市場中處於領先地位。下一代掃描儀的引入，例如亞利桑那州的Omni Legend 32 PET/CT（2024年），標誌著醫療技術的持續現代化。

歐洲

市場成長主要受癌症病例增加及PET造影劑應用範圍擴大的推動。 2025年，Telix Pharmaceuticals的Illuccix在瑞典獲批，用於輔助晚期攝護腺癌的影像診斷。

亞太地區

由於醫療保健系統的擴張、篩檢計畫的增加以及示蹤劑商業化合作的增加（例如Curium與日本PeptiDream的合作），預計亞太市場將實現最高的複合年增長率。

拉丁美洲、中東和非洲

由於癌症發生率上升以及PET-CT系統安裝量的增加（包括巴西和沙烏地阿拉伯的新中心），這些地區具有強勁的成長潛力。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家癌症盛行率
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）
  • 腫瘤PET技術進展

第五章：全球腫瘤正子斷層掃描市場分析、洞察與預測 2019-2032

  • 市場分析、洞察與預測 - 按支付方式劃分
    • 公共支付
    • 私人醫療保險/自費
  • 市場分析、洞察與預測 - 按服務提供者劃分
    • 醫院
    • 診斷中心
    • 其他
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美腫瘤正子斷層掃描市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 美國州/省
    • 加拿大

第七章：歐洲腫瘤正子斷層掃描市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區腫瘤正子斷層掃描市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 其他地區亞太地區

第九章：拉丁美洲腫瘤正子斷層掃描市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲腫瘤正子斷層掃描市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
  • GE醫療
  • Sonic Healthcare Limited
  • Oncovision
  • 皇家飛利浦
  • Apex Radiology
  • Alliance Medical Limited
  • Novant Health
  • 佳能醫療系統
  • Dignity Health
  • Concord Medical
  • 西門子醫療股份有限公司
  • Mediworks
  • 其他主要參與者
Product Code: FBI113540

Growth Factors of oncology positron emission tomography (PET) scan Market

The global oncology positron emission tomography (PET) scan market continues to expand as cancer incidence rises and demand for accurate diagnostic imaging intensifies. The market was valued at USD 11.74 billion in 2024, is expected to reach USD 12.31 billion in 2025, and is projected to rise to USD 18.04 billion by 2032, reflecting a CAGR of 5.6% during the forecast period. North America accounted for 52.55% of the market share in 2024, supported by strong technological adoption, extensive imaging infrastructure, and high cancer screening rates.

Oncology PET scans serve as critical tools for staging cancer, guiding treatment decisions, and evaluating therapeutic response. This non-invasive imaging technique, driven by radiotracers, allows clinicians to detect metabolic activity at a cellular level, making it indispensable for early cancer detection. The increasing prevalence of cancer worldwide, investment in PET infrastructure, and emergence of advanced PET/CT systems are accelerating global adoption.

Market Dynamics

Market Drivers

A major driver of market expansion is the rising global cancer burden, leading to the implementation of national screening programs and rapid deployment of advanced imaging systems. Healthcare organizations globally are adopting PET scans due to their high diagnostic accuracy and value in personalized cancer treatment. Updated clinical guidelines, such as the 2022 SNMMI and NCCN endorsement of novel PET agents like PYLARIFY for prostate cancer, further support adoption.

Growing emphasis on early diagnosis, precision oncology, and therapy monitoring continues to push demand for PET imaging. As per the American Cancer Society, over 313,780 new cases of prostate cancer are expected in the U.S. in 2025, underscoring the need for enhanced diagnostic modalities.

Market Restraints

A major challenge remains the high cost of PET systems, which restricts penetration in developing markets. Entry-level scanners cost approximately USD 475,000, while high-end scanners exceed USD 750,000, making installation and maintenance financially burdensome for smaller hospitals. Additionally, radiotracer preparation, staff expertise, and infrastructure add to operational costs.

Reimbursement limitations further hinder accessibility. In several developing economies, PET scans remain underfunded or partially covered, creating barriers to diagnostic adoption. Even in developed regions, insurance may not support multiple scans or certain cancer types, limiting market utilization.

Market Opportunities

Integration of artificial intelligence (AI) in oncology PET imaging presents significant opportunities. AI tools enhance lesion detection, automate tumor quantification, and improve workflow efficiency. For instance, Siemens Healthineers' Biograph Vision PET/CT, launched in 2023, features advanced time-of-flight imaging that improves diagnostic clarity. As AI-enabled systems gain regulatory approvals, their adoption is poised to accelerate PET imaging efficiency globally.

Market Challenges

Persistent radiotracer supply chain constraints represent a crucial challenge. Radiotracers such as FDG have short half-lives, demanding efficient logistics. Any delay disrupts scheduling and increases waiting times. In the U.K., 2024 data showed 92% of cancer patients waited at least 31 days for screenings, partly due to radiotracer bottlenecks. Global dependence on limited isotope suppliers also makes health systems vulnerable to production disruptions.

Market Trends

A defining trend is the shift toward theranostics, which combines diagnostic PET imaging with targeted radionuclide therapy. PSMA-based PET imaging for prostate cancer and novel tracers for neuroendocrine tumors illustrate the growing interest in precision oncology. Advancements in imaging biomarkers are also transforming treatment planning by enabling prediction of therapy outcomes and real-time monitoring.

Segmentation Overview

By Source of Payment

The private insurance/out-of-pocket segment dominated 2024, driven by patient preference for faster access to premium oncology diagnostics. Rising cancer treatment costs reinforce the shift toward private spending. The public segment also grew due to global efforts to integrate PET imaging into government-funded cancer programs.

By Service Provider

Hospitals dominated the market in 2024, backed by advanced imaging infrastructure and trained radiology teams. Diagnostic centers, however, are projected to grow fastest due to cost-effectiveness, shorter wait times, and rising investments in PET/CT acquisition.

Regional Overview

North America (USD 6.17 billion in 2024)

The region leads globally due to strong healthcare infrastructure and high adoption of advanced PET systems. Installations of new-generation scanners-such as Omni Legend 32 PET/CT in Arizona (2024)-highlight ongoing modernization.

Europe

Market growth is driven by rising cancer cases and expansion of PET imaging agents. In 2025, Telix Pharmaceuticals' Illuccix received Swedish approval, supporting advanced prostate cancer imaging.

Asia Pacific

Expected to record the highest CAGR, driven by expanding healthcare systems, growing screening programs, and rising tracer commercialization partnerships, such as Curium and PeptiDream's collaboration in Japan.

Latin America & Middle East-Africa

These regions show strong growth potential due to increasing cancer prevalence and expanding installation of PET CT systems, including new centers in Brazil and Saudi Arabia.

Conclusion

Driven by rising cancer cases, AI integration, and advancements in theranostics, the oncology PET scan market is projected to increase from USD 11.74 billion in 2024 to USD 18.04 billion by 2032. Continuous investments in next-generation PET technologies will continue shaping the global cancer diagnostics landscape.

Segmentation By Source of Payment

  • Public
  • Private Health Insurance/Out-of-pocket

By Service Providers

  • Hospitals
  • Diagnostic Centers
  • Others

By Region

  • North America (By Source of Payment, Service Providers, and Country)
    • U.S.
    • Canada
  • Europe (By Source of Payment, Service Providers, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Source of Payment, Service Providers, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Source of Payment, Service Providers, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Source of Payment, Service Providers, and Country/Sub-region)
    • GCC
    • South Africa
  • Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer, Key Countries
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
  • 4.4. Technological Advancements in Oncology PET

5. Global Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 5.1.1. Public
    • 5.1.2. Private Health Insurance/Out-of-pocket
  • 5.2. Market Analysis, Insights and Forecast - By Service Providers
    • 5.2.1. Hospitals
    • 5.2.2. Diagnostic Centers
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 6.1.1. Public
    • 6.1.2. Private Health Insurance/Out-of-pocket
  • 6.2. Market Analysis, Insights and Forecast - By Service Providers
    • 6.2.1. Hospitals
    • 6.2.2. Diagnostic Centers
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 7.1.1. Public
    • 7.1.2. Private Health Insurance/Out-of-pocket
  • 7.2. Market Analysis, Insights and Forecast - By Service Providers
    • 7.2.1. Hospitals
    • 7.2.2. Diagnostic Centers
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 8.1.1. Public
    • 8.1.2. Private Health Insurance/Out-of-pocket
  • 8.2. Market Analysis, Insights and Forecast - By Service Providers
    • 8.2.1. Hospitals
    • 8.2.2. Diagnostic Centers
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 9.1.1. Public
    • 9.1.2. Private Health Insurance/Out-of-pocket
  • 9.2. Market Analysis, Insights and Forecast - By Service Providers
    • 9.2.1. Hospitals
    • 9.2.2. Diagnostic Centers
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Oncology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Source of Payment
    • 10.1.1. Public
    • 10.1.2. Private Health Insurance/Out-of-pocket
  • 10.2. Market Analysis, Insights and Forecast - By Service Providers
    • 10.2.1. Hospitals
    • 10.2.2. Diagnostic Centers
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. GE Healthcare
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sonic Healthcare Limited
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Oncovision
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Koninklijke Philips N.V.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Apex Radiology
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Alliance Medical Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Novant Health
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Canon Medical Systems
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Dignity Health
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Concord Medical
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Siemens Healthcare Limited
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)
    • 11.2.12. Mediworks
      • 11.2.12.1. Overview
      • 11.2.12.2. Products
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. Financials (Based on Availability)
    • 11.2.13. Other Prominent Players
      • 11.2.13.1. Overview
      • 11.2.13.2. Products
      • 11.2.13.3. SWOT Analysis
      • 11.2.13.4. Recent Developments
      • 11.2.13.5. Strategies
      • 11.2.13.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 2: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 3: Global Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 4: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 5: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 6: North America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 7: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 8: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 9: Europe Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 11: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 12: Asia Pacific Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 14: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 15: Latin America Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Source of Payment, 2019-2032
  • Table 17: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, by Service Providers, 2019-2032
  • Table 18: Middle East & Africa Oncology Positron Emission Tomography Scan Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Oncology Positron Emission Tomography Scan Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024 & 2032
  • Figure 3: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024 & 2032
  • Figure 4: Global Oncology Positron Emission Tomography Scan Market Value Share (%), by Region, 2024 & 2032
  • Figure 5: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 6: North America Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 7: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 8: North America Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 9: North America Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country, 2024 & 2032
  • Figure 10: North America Oncology Positron Emission Tomography Scan Market Value Share (%), By Country, 2024
  • Figure 11: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 12: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 13: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 14: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 15: Europe Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 16: Europe Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 17: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 18: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 19: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 20: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 21: Asia Pacific Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Asia Pacific Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 24: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 25: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 26: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 27: Latin America Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 28: Latin America Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 29: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), by Source of Payment, 2024 & 2032
  • Figure 30: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), by Source of Payment, 2024
  • Figure 31: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), by Service Providers, 2024 & 2032
  • Figure 32: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), by Service Providers, 2024
  • Figure 33: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 34: Middle East & Africa Oncology Positron Emission Tomography Scan Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 35: Global Oncology Positron Emission Tomography Scan Market Share (%), By Company, 2024